Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 01, 2019 07:00 ET | Source: Akorn, Inc.

Akorn Provides Preliminary Second Quarter 2019 Results

LAKE FOREST, Ill., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced its preliminary financial results for the second...
July 11, 2019 16:32 ET | Source: Akorn, Inc.

Akorn to Report Second Quarter 2019 Financial Results and Host Conference Call

LAKE FOREST, Ill., July 11, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it plans to issue a press release before...
June 28, 2019 07:00 ET | Source: Akorn, Inc.

Akorn Announces Launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5%

LAKE FOREST, Ill., June 28, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it has launched its first-to-market generic...
June 25, 2019 07:35 ET | Source: Akorn, Inc.

Akorn Receives FDA Warning Letter

LAKE FOREST, Ill., June 25, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, announced that it received a warning letter from the U.S. Food...
May 30, 2019 07:59 ET | Source: Akorn, Inc.

Akorn to Present at the Jefferies 2019 Global Healthcare Conference

LAKE FOREST, Ill., May 30, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that management will present at the Jefferies 2019...
May 20, 2019 16:05 ET | Source: Akorn, Inc.

Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.1%

LAKE FOREST, Ill., May 20, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug...
May 20, 2019 08:01 ET | Source: Akorn, Inc.

Akorn to Present at the RBC Capital Markets Healthcare Conference

LAKE FOREST, Ill., May 20, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that management will present at the 2019 RBC...
May 07, 2019 07:05 ET | Source: Akorn, Inc.

Akorn Provides Preliminary First Quarter 2019 Results and Full Year Guidance

-Operational improvements drive sequential growth- -Full year outlook anticipates further sequential growth throughout the year- LAKE FOREST, Ill., May 07, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc....
April 18, 2019 17:00 ET | Source: Akorn, Inc.

Akorn Receives FDA Approval for Loteprednol Etabonate Ophthalmic Suspension, 0.5%

LAKE FOREST, Ill., April 18, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug...
April 18, 2019 16:05 ET | Source: Akorn, Inc.

Akorn Receives FDA Approval for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC)

LAKE FOREST, Ill., April 18, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug...